Abstract：
UNASSIGNED: Stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) are increasingly used as initial therapies for brain metastases (BM). We aimed to assess the outcomes of SRS/FSRT in patients aged ≥65 years who had 1-10 BM from non-small cell lung cancer (NSCLC).
UNASSIGNED: We retrospectively reviewed 91 elderly NSCLC patients with 222 BM who were treated with SRS/FSRT at two institutions between 2010 and 2020. The primary endpoint was overall survival (OS) after SRS/FSRT. In addition, in-field local control (IFLC) within the treated field was evaluated. Statistical analysis was performed to identify the prognostic factors affecting OS and IFLC.
UNASSIGNED: During a median follow-up of 18 months, the median OS was 32 months. The 1- and 2-year survival rates were 69.8 and 56.1%, respectively. In multivariate analysis, the NSCLC-specific graded prognostic assessment (GPA) score (p=0.007) and administration of systemic therapy (p=0.039) were defined as prognosticators affecting OS. The median IFLC period was 31 months, and the 1- and 2-year IFLC rates were 75.9 and 57.6%, respectively. The total BM volume (p=0.042) significantly affected IFLC. No severe adverse events were reported after SRS/FSRT.
UNASSIGNED: SRS/FSRT is an effective upfront treatment option for BM arising from NSCLC in elderly patients, with a good OS without severe side effects. Higher GPA score and active systemic treatment were associated with improved OS, indicating that elderly patients are significant candidates for SRS/FSRT.
UNASSIGNED: We retrospectively reviewed 91 elderly NSCLC patients with 222 BM who were treated with SRS/FSRT at two institutions between 2010 and 2020. The primary endpoint was overall survival (OS) after SRS/FSRT. In addition, in-field local control (IFLC) within the treated field was evaluated. Statistical analysis was performed to identify the prognostic factors affecting OS and IFLC.
UNASSIGNED: During a median follow-up of 18 months, the median OS was 32 months. The 1- and 2-year survival rates were 69.8 and 56.1%, respectively. In multivariate analysis, the NSCLC-specific graded prognostic assessment (GPA) score (p=0.007) and administration of systemic therapy (p=0.039) were defined as prognosticators affecting OS. The median IFLC period was 31 months, and the 1- and 2-year IFLC rates were 75.9 and 57.6%, respectively. The total BM volume (p=0.042) significantly affected IFLC. No severe adverse events were reported after SRS/FSRT.
UNASSIGNED: SRS/FSRT is an effective upfront treatment option for BM arising from NSCLC in elderly patients, with a good OS without severe side effects. Higher GPA score and active systemic treatment were associated with improved OS, indicating that elderly patients are significant candidates for SRS/FSRT.
摘要：
■立体定向放射外科（SRS）或分割立体定向放射治疗（FSRT）越来越多地用作脑转移瘤（BM）的初始疗法。我们旨在评估年龄≥65岁的非小细胞肺癌（NSCLC）患者的SRS/FSRT结果。
■我们回顾性回顾了2010年至2020年间在两个机构接受SRS/FSRT治疗的91例老年NSCLC患者，其中222例BM。主要终点是SRS/FSRT后的总生存期(OS)。此外,评估治疗场内的场内局部控制(IFLC).进行统计学分析以确定影响OS和IFLC的预后因素。
■在18个月的中位随访期间，中位OS为32个月.1年和2年生存率分别为69.8％和56.1％，分别。在多变量分析中，NSCLC特异性分级预后评估(GPA)评分(p=0.007)和全身治疗(p=0.039)被定义为影响OS的预后因素.IFLC的中位数为31个月，1年和2年IFLC比率分别为75.9%和57.6%，分别。总BM体积(p=0.042)显著影响IFLC。SRS/FSRT后未报告严重不良事件。
■SRS/FSRT是老年患者NSCLC引起的BM的有效前期治疗选择。具有良好的操作系统，没有严重的副作用。较高的GPA评分和积极的全身治疗与改善的OS相关。表明老年患者是SRS/FSRT的重要候选人。
■我们回顾性回顾了2010年至2020年间在两个机构接受SRS/FSRT治疗的91例老年NSCLC患者，其中222例BM。主要终点是SRS/FSRT后的总生存期(OS)。此外,评估治疗场内的场内局部控制(IFLC).进行统计学分析以确定影响OS和IFLC的预后因素。
■在18个月的中位随访期间，中位OS为32个月.1年和2年生存率分别为69.8％和56.1％，分别。在多变量分析中，NSCLC特异性分级预后评估(GPA)评分(p=0.007)和全身治疗(p=0.039)被定义为影响OS的预后因素.IFLC的中位数为31个月，1年和2年IFLC比率分别为75.9%和57.6%，分别。总BM体积(p=0.042)显著影响IFLC。SRS/FSRT后未报告严重不良事件。
■SRS/FSRT是老年患者NSCLC引起的BM的有效前期治疗选择。具有良好的操作系统，没有严重的副作用。较高的GPA评分和积极的全身治疗与改善的OS相关。表明老年患者是SRS/FSRT的重要候选人。
